Innate Pharma S.A. (IPHYF)
USD 1.45
(7.41%)
USD 1.45
(7.41%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 51.9 Million EUR | 4.56% |
| 2022 | 49.63 Million EUR | 309.83% |
| 2021 | 12.11 Million EUR | -78.69% |
| 2020 | 56.83 Million EUR | -17.6% |
| 2019 | 68.97 Million EUR | -13.67% |
| 2018 | 79.89 Million EUR | 144.83% |
| 2017 | 32.63 Million EUR | -41.9% |
| 2016 | 56.16 Million EUR | 213.64% |
| 2015 | 17.9 Million EUR | 1874.2% |
| 2014 | 907 Thousand EUR | -92.73% |
| 2013 | 12.46 Million EUR | 20.16% |
| 2012 | 10.37 Million EUR | -11.61% |
| 2011 | 11.74 Million EUR | 171.76% |
| 2010 | 4.32 Million EUR | -44.01% |
| 2009 | 7.71 Million EUR | -40.3% |
| 2008 | 12.92 Million EUR | -9.56% |
| 2007 | 14.29 Million EUR | 130.67% |
| 2006 | 6.19 Million EUR | 376.54% |
| 2005 | 1.3 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 6.17 Million EUR | 0.0% |
| 2024 Q1 | 6.17 Million EUR | -42.43% |
| 2023 Q2 | 35.34 Million EUR | 75.85% |
| 2023 Q3 | 10.72 Million EUR | -69.67% |
| 2023 Q4 | 10.72 Million EUR | 0.0% |
| 2023 FY | 51.9 Million EUR | 4.56% |
| 2023 Q1 | 20.09 Million EUR | 141.89% |
| 2022 FY | 49.63 Million EUR | 309.83% |
| 2022 Q2 | 41.27 Million EUR | 81.06% |
| 2022 Q1 | 22.79 Million EUR | 716.13% |
| 2022 Q4 | 8.3 Million EUR | 37.51% |
| 2022 Q3 | 6.04 Million EUR | -85.36% |
| 2021 Q2 | 9.31 Million EUR | 40.01% |
| 2021 Q3 | 5.69 Million EUR | -38.88% |
| 2021 Q4 | 2.79 Million EUR | -50.96% |
| 2021 FY | 12.11 Million EUR | -78.69% |
| 2021 Q1 | 6.65 Million EUR | -75.34% |
| 2020 Q4 | 26.99 Million EUR | 60.16% |
| 2020 Q1 | 18.37 Million EUR | 5.67% |
| 2020 Q2 | 29.84 Million EUR | 62.42% |
| 2020 Q3 | 16.85 Million EUR | -43.52% |
| 2020 FY | 56.83 Million EUR | -17.6% |
| 2019 Q2 | 51.58 Million EUR | 74.42% |
| 2019 Q1 | 29.57 Million EUR | -16.63% |
| 2019 Q3 | 13.32 Million EUR | -74.16% |
| 2019 Q4 | 17.38 Million EUR | 30.43% |
| 2019 FY | 68.97 Million EUR | -13.67% |
| 2018 Q2 | 11.49 Million EUR | 0.0% |
| 2018 FY | 79.89 Million EUR | 144.83% |
| 2018 Q1 | 11.49 Million EUR | 1.04% |
| 2018 Q4 | 35.47 Million EUR | 0.0% |
| 2018 Q3 | 35.47 Million EUR | 208.56% |
| 2017 Q2 | 10.63 Million EUR | 0.0% |
| 2017 FY | 32.63 Million EUR | -41.9% |
| 2017 Q4 | 11.37 Million EUR | 0.0% |
| 2017 Q3 | 11.37 Million EUR | 6.98% |
| 2017 Q1 | 10.63 Million EUR | -52.76% |
| 2016 FY | 56.16 Million EUR | 213.64% |
| 2016 Q1 | 10.34 Million EUR | 0.9% |
| 2016 Q2 | 10.34 Million EUR | 0.0% |
| 2016 Q3 | 22.51 Million EUR | 117.72% |
| 2016 Q4 | 22.51 Million EUR | 0.0% |
| 2015 FY | 17.9 Million EUR | 1874.2% |
| 2015 Q4 | 10.25 Million EUR | 0.0% |
| 2015 Q3 | 10.25 Million EUR | 341.83% |
| 2015 Q2 | 2.32 Million EUR | 0.0% |
| 2015 Q1 | 2.32 Million EUR | 33.1% |
| 2014 Q1 | 2.06 Million EUR | -57.23% |
| 2014 FY | 907 Thousand EUR | -92.73% |
| 2014 Q4 | 1.74 Million EUR | 0.0% |
| 2014 Q3 | 1.74 Million EUR | -15.74% |
| 2014 Q2 | 2.06 Million EUR | 0.0% |
| 2013 Q4 | 4.83 Million EUR | 0.0% |
| 2013 Q3 | 4.83 Million EUR | 38.62% |
| 2013 Q1 | 3.48 Million EUR | 6.32% |
| 2013 FY | 12.46 Million EUR | 20.16% |
| 2013 Q2 | 3.48 Million EUR | 0.0% |
| 2012 Q3 | 3.28 Million EUR | 0.0% |
| 2012 Q4 | 3.28 Million EUR | 0.0% |
| 2012 FY | 10.37 Million EUR | -11.61% |
| 2011 FY | 11.74 Million EUR | 171.76% |
| 2010 FY | 4.32 Million EUR | -44.01% |
| 2009 FY | 7.71 Million EUR | -40.3% |
| 2008 FY | 12.92 Million EUR | -9.56% |
| 2007 FY | 14.29 Million EUR | 130.67% |
| 2006 FY | 6.19 Million EUR | 376.54% |
| 2005 FY | 1.3 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioxytran, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -229.05% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -141.647% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -78863.303% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -184.889% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 57.788% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 645.81 Thousand USD | -7936.574% |
| Genus plc | 668.8 Million USD | 92.24% |
| Pharming Group N.V. | 245.31 Million USD | 78.843% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -52328.43% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -12553.688% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -67513.762% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -131235.088% |
| ONE Bio Corp. | 52.29 Million USD | 0.756% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -4.384% |
| Mesoblast Limited | 5.9 Million USD | -779.38% |
| MultiCell Technologies, Inc. | 49.32 USD | -105233071.127% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -75.359% |
| Genscript Biotech Corporation | 839.52 Million USD | 93.818% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -294440.605% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -9206.091% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -74044.286% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -68439.697% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -7781.701% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -106037.014% |
| Q BioMed Inc. | 284.35 Thousand USD | -18152.377% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.647% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 64.231% |
| Enzolytics Inc. | 52.79 Thousand USD | -98204.796% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -8428.984% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 95.768% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -2586.387% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -5195195.295% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -36908.172% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -8306.599% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -5101.929% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -7.335% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -211.056% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -21839.888% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -21839.888% |
| Affymax, Inc. | 1.36 Million USD | -3691.161% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -566.337% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -10855.819% |
| SYBLEU INC | 11.69 Thousand USD | -443650.0% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -399138.462% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -131181.935% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -1458.589% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -678.71% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -4895.284% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -101.424% |
| CSL Limited | 14.8 Billion USD | 99.649% |
| Cellectis S.A. | 755 Thousand USD | -6774.305% |